Stromal cells play a role in cervical cancer progression mediated by MMP-2 protein

Metalloproteinases, especially metal loprotemase-2 (MMP-2), are known for their role in the degradation of the extracellular matrix. Nevertheless, a thorough understanding of MMP-2 expression in neoplastic lesions of the uterine cervix has yet to be accomplished. This study aimed to analyze the MMP-2 expression in cervical intraepithelial neoplasia III (CIN3) and in cervical squamous cell carcinoma, in tumor cells and adjacent stromal cells. MMP-2 expression was assessed by an immunohistochernical technique. MMP-2 expression was greater in the stromal cells of invasive carcinomas than in CIN3 (p < 0.0001). MMP-2 expression in stromal cells correlates with the clinical stage, gradually increasing as the tumor progresses (p = 0.04). This study corroborates that stromal cells play an important role in tumor invasion and progression, mediated by the progressive enhancement of MMP-2 expression from CIN3 to advanced invasive tumor. The intense MMP-2 expression most probably is associated with poor tumor prognosis.

Matrix metalloproteinase 2; Cervix cancer; Cervical intraepithelial neoplasia; Stromal cells

[1] International Agency for Research on Cancer. Cancer Epidemiolgy Databases. Globocan 2002 http://www-depdb.iarc.fr/globocan/ GLOBOframe.htm, 2007.

[2] Burd E.M.: “Human papillomavirus and cervical cancer”. Clin. Microbiol. Rev., 2003, 16, 1.

[3]Itoh Y., Nagase H.: “Matrix metalloproteinases in cancer”. Essays Biochem., 2002, 38, 21.

[4] Zhou C.Y., Yao J.F., Chen X.D.: “Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix”. Ai Zheng, 2002, 2, 735.

[5]Benaud C., Dickson R.B., Thompson E.W.: “Roles of the matrix metalloproteinases in mammary gland development and cancer”. Breast Cancer Res. Treat., 1998, 50, 97.

[6] Baker A.H., Edwards D.R., Murphy G.: “Metalloproteinase inhibitors: biological actions and therapeutic opportunities”. J. Cell. Sci, 2002, 115, 3719.

[7] Brummer O., Bohmer G., Hollwitz B., Flemming P., Petry K.U., Kuhnle H.: “MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation-an immunohistochemical study”. Gynecol. Oncol., 2002, 84, 222.

[8] Singer C.F., Kronsteiner N., Marton E., Kubista M., Cullen K.J., Hirtenlehner K. et al.: “MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions”. Breast Cancer Res. Treat., 2002, 72, 69.

[9] Aznavoorian S., Murphy A.N., Stetler-Stevenson W.G., Liotta L.A.: “Molecular aspects of tumor cell invasion and metastasis”. Cancer, 1993, 71, 1368.

[10] Imai K., Ohuchi E., Aoki T., Nomura H., Fujii Y., Sato H. et al.: “Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinase 2”. Cancer Res., 1996, 56, 2707.

[11] van der Jagt M.F., Sweep F.C., Waas E.T., Hendriks T., Ruers T.J., Merry A.H.: “Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer”. Cancer Lett., 2006, 237, 289.

[12] Masui T., Doi R., Koshiba T., Fujimoto K., Tsuji S., Nakajima S., et al.: “RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis”. Clin. Cancer Res., 2003, 9, 1779.

[13] Boag A.H., Young I.D.: “Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization”. Am. J. Pathol., 1994, 144, 585.

[14] Davies B., Waxman J., Wasan H., Abel P., Williams G., Krausz T., et al.: “Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion”. Cancer Res., 1993, 53, 5365.

[15] Pellikainen J.M., Ropponen K.M., Kataja V.V., Kellokoski J.K., Eskelinen M.J., Kosma V.M.: “Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER-2, and prognosis”. Clin. Cancer Res., 2004, 10, 7621.

[16] Gaiotto M.A., Focchi J., Ribalta J., Stávale J.N., Baracat E.C., Lima G.R. et al.: “Comparative study of MMP-2 immune expression in normal uterine cervix, intraepithelial neoplasias, and squamous cells cervical carcinoma”. Am. J. Obstet. Gynecol., 2004, 190, 1278.

[17] Branca M., Ciotti M., Giorgi C., Santini D., Di Bonito L., Costa S. et al.: “Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN”. Anticancer Res., 2006, 26, 1543.

[18] Davidson B., Goldberg I., Kopolovic J., Lener-Geva L., Gotlieb W.H., Ben-Baruch G. et al.: “MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization”. Gynecol. Oncol., 1999, 73, 372.

[19] Ishikawa S., Takenaka K., Yanagihara K., Miyahara R., Kawano Y., Otake Y. et al.: “Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell-lung cancer”. Clin. Cancer Res., 2004, 10, 6579.

[20] Masaki T., Matsuoka H., Sugiyama M., Abe N., Izumisato Y., Goto A. et al.: “Laminin-5 gamma 2 chain and matrix metalloproteinase-2 may trigger colorectal carcinoma invasiveness through formation of budding tumor cells”. Anticancer Res., 2003, 23, 4113.

[21] Sun J., Hemler M.E.: “Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions”. Cancer Res., 2001, 61, 2276.

[22] Sier C.F., Zuidwijk K., Zijlmans H.J., Hanemaaijer R., Mulder-Stapel A.A., Prins F.A. et al.: “EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma”. Int. J. Cancer, 2006, 118, 2991.

[23] Smola-Hess S., Pahne J., Mauch C., Zigrino P., Smola H., Pfister H.: “Expression of membrane type 1 matrix metalloproteinase in papillomavirus-positive cell: role of the human papillomavirus (HPV) 16 and HPV8 E7 gene products”. J. Gen. Virol., 2005, 86, 1291.